AlphaStocks
3.5
Weak

Lemaitre Vascular Inc (LMAT)

As of Sep 20, 2026, Lemaitre Vascular Inc (LMAT) scores 3.5/10 on AlphaStocks' five-model composite, #148 of 168 Health Care stocks. At $79, LMAT trades 17% above its model fair value of $67.

Health Care / Health Care Equipment

S&P SmallCap 600

$78.88

Scores poorly across most models. Proceed with caution.

Weak

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#148out of 168 in Health Care

Is LEMAITRE VASCULAR INC a Good Investment in 2026?

LEMAITRE VASCULAR INC (LMAT) scores 3.5 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates LEMAITRE VASCULAR INC as Attractive (6/9). However, the Greenblatt Magic Formula model rates it Caution — Earnings yield 2.7% · ROC 15%. LEMAITRE VASCULAR INC currently trades 17% above its estimated fair value of $67. LEMAITRE VASCULAR INC ranks #148 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E31.3ROE14.9Market Cap2BDiv Yield0.8

Estimated Fair Value

$67.4217% above

Trading above estimated fair value — the market may be pricing in future growth.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

6/9

Buffett

Attractive

Business quality & competitive moat

Graham

Neutral

Significantly above fair value

Lynch

Neutral

PEG 1.9 · Fast Grower

Greenblatt

Caution

Earnings yield 2.7% · ROC 15%

Frequently Asked Questions

Is LEMAITRE VASCULAR INC (LMAT) a good investment?
As of Sep 20, 2026, Lemaitre Vascular Inc (LMAT) scores 3.5/10 on AlphaStocks' five-model composite, #148 of 168 Health Care stocks. At $79, LMAT trades 17% above its model fair value of $67. That score is below average, suggesting caution.
What is LEMAITRE VASCULAR INC's Piotroski F-Score?
LEMAITRE VASCULAR INC's Piotroski F-Score status is Attractive. The raw score is 6/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is LMAT overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $67, LMAT appears overvalued. The stock currently trades 17% above its estimated fair value. Trading above estimated fair value — the market may be pricing in future growth.
How does LMAT compare to other Health Care stocks?
LEMAITRE VASCULAR INC ranks #148 out of 168 stocks in the Health Care sector, placing it in the top 88% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about LMAT?
AlphaStocks evaluates LMAT using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 3.5/10.

Similar Stocks

INSPUFPTBDX

Compare LMAT with

INSP vs LMATLMAT vs UFPTBDX vs LMAT

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer